secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001171843-26-003154
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corvus reports Q1 2026 net loss of $13.7M; cash $236.7M; soquelitinib trials advance
--------------------------------------------------------------------------------

- Net loss $13.7M in Q1 2026 vs net income $15.2M in Q1 2025; cash $236.7M (incl. $189.4M from Jan 2026 financing).
- Phase 2 atopic dermatitis trial initiated (~200 patients, 4 dose cohorts, 12-week treatment).
- Phase 3 registrational PTCL trial enrolling 150 patients; primary endpoint progression-free survival.
- Partner Angel Pharma enrolling Phase 1b/2 atopic dermatitis trial in China; initial results expected late 2026.
- New immunologic/biomarker data from Phase 1 to be presented at SID meeting on May 14, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000117184326003154/0001171843-26-003154-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000117184326003154/f8k_050726.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-003154

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer